bluebird bio Has Promising Results from Its Lenti-D Gene Therapy for CALD
Good results have come from bluebird bio’s (BLUE) updated results in the clinical development program for its investigational Lenti-D™ gene therapy in patients with cerebral adrenoleukodystrophy (CALD) at the 13th European Pediatric Neurology Society (EPNS) Congress in Athens, Greece.
bluebird bio's Starbeam Trial . . .
This content is for paid subscribers.
Today’s Highlights September 20, 2019